Medtronic, Inc, today announced highlights of clinical data presentations scheduled for the 2009 American College of Cardiology (ACC) meeting that feature the company’s cardiovascular innovations, including the Endeavor Drug-Eluting Stent (DES) and the Export Aspiration Catheter. ACC.09 takes place in Orlando March 28–31 at the Orange County Convention Center.
Late-Breaking Clinical Trials
Clinical data on the Endeavor DES will be presented in the following late-breaking clinical trial session:
Sunday, March 29
i.2 Plenary.2406 – Valencia Ballroom W415
* ZEST / 08:00 – 08:12
(2406-7) Comparison of Sirolimus- and Paclitaxel-Eluting Stents Versus Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial, by Seung-Jung Park (Seoul, South Korea) et al.
Oral and Poster Contributions
Additional data related to Medtronic’s cardiovascular medical technologies will also be released in the following i.2 poster contributions starting Saturday:
* E-Five Registry
(2510-644) Two-Year Extended Follow-Up in Patients Receiving a Zotarolimus-Eluting Stent in the E-Five Registry, by Martin Rothman (London, England) et al.
(2501-521) Predictors of Major Adverse Cardiac Events in a Real-World Population Receiving the Zotarolimus-Eluting Stent: Data from the E-Five Registry, by Chaim Lotan (Jerusalem, Israel) et al.
(2501-533) The Safety and Efficacy of the Zotarolimus-Eluting Stent in Elderly Patients: 12-Month Outcomes from the E-Five Registry, by Chaim Lotan (Jerusalem, Israel) et al.
(2520-787) The Effect of Renal Impairment on Outcomes from the Real-World E-Five Registry, by Martin Rothman (London, England) et al.
* SENS Registry
(2501-543) Outcome of Non-cardiac Surgical Procedure and Brief Interruption of Dual Antiplatelet Agents within 12 Months Following Endeavor Stent Implantation (SENS): A Multicenter Study, by Jin Won Kim (Seoul, South Korea) et al.
* TAPAS-II
(2514-721) One-Year Follow-Up of Thrombus Aspiration During Primary Percutaneous Coronary Intervention in Acute Non-ST-Elevation Myocardial Infarction Study, by Pieter Vlaar (Groningen, the Netherlands) et al.
These posters will be on display at various times on Sunday and Monday.
In addition, Medtronic will feature highlights of its current and future cardiovascular innovations at ACC.09 (booth number 2743).
ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Contact:
Medtronic, Inc.
Joseph McGrath, 707-591-7367
Public Relations
or
Jeff Warren, 763-505-2696
Investor Relations
source: yahoo
Late-Breaking Clinical Trials
Clinical data on the Endeavor DES will be presented in the following late-breaking clinical trial session:
Sunday, March 29
i.2 Plenary.2406 – Valencia Ballroom W415
* ZEST / 08:00 – 08:12
(2406-7) Comparison of Sirolimus- and Paclitaxel-Eluting Stents Versus Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial, by Seung-Jung Park (Seoul, South Korea) et al.
Oral and Poster Contributions
Additional data related to Medtronic’s cardiovascular medical technologies will also be released in the following i.2 poster contributions starting Saturday:
* E-Five Registry
(2510-644) Two-Year Extended Follow-Up in Patients Receiving a Zotarolimus-Eluting Stent in the E-Five Registry, by Martin Rothman (London, England) et al.
(2501-521) Predictors of Major Adverse Cardiac Events in a Real-World Population Receiving the Zotarolimus-Eluting Stent: Data from the E-Five Registry, by Chaim Lotan (Jerusalem, Israel) et al.
(2501-533) The Safety and Efficacy of the Zotarolimus-Eluting Stent in Elderly Patients: 12-Month Outcomes from the E-Five Registry, by Chaim Lotan (Jerusalem, Israel) et al.
(2520-787) The Effect of Renal Impairment on Outcomes from the Real-World E-Five Registry, by Martin Rothman (London, England) et al.
* SENS Registry
(2501-543) Outcome of Non-cardiac Surgical Procedure and Brief Interruption of Dual Antiplatelet Agents within 12 Months Following Endeavor Stent Implantation (SENS): A Multicenter Study, by Jin Won Kim (Seoul, South Korea) et al.
* TAPAS-II
(2514-721) One-Year Follow-Up of Thrombus Aspiration During Primary Percutaneous Coronary Intervention in Acute Non-ST-Elevation Myocardial Infarction Study, by Pieter Vlaar (Groningen, the Netherlands) et al.
These posters will be on display at various times on Sunday and Monday.
In addition, Medtronic will feature highlights of its current and future cardiovascular innovations at ACC.09 (booth number 2743).
ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Contact:
Medtronic, Inc.
Joseph McGrath, 707-591-7367
Public Relations
or
Jeff Warren, 763-505-2696
Investor Relations
source: yahoo
0 comments:
Post a Comment